Details

Published: 11 September 2025

Hits: 477

The spectacular collapse of the cannabis industry serves as a stark vindication for prevention advocates who warned against the normalisation of marijuana use. What proponents once promised would be a responsible, regulated market has devolved into a cautionary tale of corporate greed, public health risks, and broken societal promises.

The Cannabis Market Collapse Unfolds

The cannabis market collapse has been more dramatic than even the most pessimistic prevention experts predicted. Four major cannabis corporations – Curaleaf, Green Thumb Industries, Tilray Brands, and Trulieve Cannabis – have seen their combined valuation plummet from $37 billion in February 2021 to just $4 billion today, representing a devastating 89% decline.

This cannabis industry downturn exposes the hollow promises made by marijuana advocates who claimed legalisation would create a mature, responsible industry. Instead, the sector has become characterised by oversupply, price wars, and mounting concerns about youth accessibility and addiction.

Oversupply Creates Dangerous Market Dynamics

The rapid proliferation of cannabis outlets has created precisely the scenario prevention organisations warned against. New York’s explosion from zero to 300 registered dispensaries since 2021 demonstrates how quickly marijuana availability can spiral beyond reasonable control.

This oversaturation has driven prices down by 32% across the United States, making cannabis increasingly accessible to vulnerable populations, including young people. The cannabis market collapse has ironically made the drug more affordable and widespread than prohibition advocates feared.

Youth Protection Failures Mount

Thailand’s recent decision to reverse cannabis legalisation highlights growing international concern about youth addiction – a primary concern raised by prevention advocates from the beginning. The country’s policy reversal came specifically in response to rising addiction rates amongst younger users, validating longstanding warnings about marijuana’s gateway potential.

This cannabis industry downturn coincides with mounting evidence of cannabis-related harms that industry proponents systematically downplayed during the legalisation push. Prevention experts who warned about normalisation effects are finding their concerns increasingly validated by real-world evidence.

Political Reality Contradicts Industry Promises

The stalling of cannabis expansion across the United States reflects growing political recognition of the policy’s failures. Not a single state has legalised recreational marijuana in 2024 or 2025, suggesting lawmakers are heeding prevention advocates’ warnings about societal costs.

President Trump’s administration appears unlikely to pursue federal cannabis reform, whilst the Drug Enforcement Administration has stalled its review of marijuana’s scheduling. This political hesitation suggests growing awareness that legalisation promises have not materialised as advertised.

International Backtracking Validates Prevention Stance

The global retreat from cannabis liberalisation vindicates prevention organisations’ warnings about premature policy adoption. Right-leaning governments worldwide are blocking new recreational markets, recognising the social costs that industry advocates failed to acknowledge.

Thailand’s cannabis ban reversal represents a broader international trend of policy reconsideration. Countries that initially embraced liberalisation are confronting the reality that cannabis normalisation creates more problems than proponents admitted.

Financial Collapse Exposes Industry Deception

The cannabis market collapse has revealed the industry’s fundamental dishonesty about its business model. Major companies are posting collective losses with forward revenue multiples barely above 1, proving that sustainable cannabis commerce was always questionable.

Corporate debt burdens and failed expansion plans demonstrate that the industry’s growth projections were fantasy rather than sound business analysis. Prevention advocates who questioned these unrealistic promises have been vindicated by market reality.

German Market Highlights Continued Risks

Industry attempts to pin hopes on Germany’s limited decriminalisation reveal the sector’s desperation following its cannabis industry downturn. However, Germany’s cautious approach – allowing only personal use whilst restricting commercial cultivation – suggests even progressive governments recognise the dangers of full liberalisation.

The German market’s tiny $37 million value underscores how limited genuine demand actually is when separated from speculative investment hype. This reality contradicts industry claims about massive unmet consumer demand that justified policy changes.

Public Health Evidence Accumulates

The cannabis market collapse coincides with growing research documenting marijuana’s health risks, particularly regarding mental health impacts and dependency potential. Studies continue revealing long-term consequences that industry advocates consistently minimised during legalisation campaigns.

Prevention organisations’ warnings about cannabis-related mental health risks are gaining scientific support, whilst industry claims about marijuana’s safety profile face increasing scrutiny. The timing of the market collapse alongside emerging health evidence suggests correlation between policy failures and public health concerns.

Prevention Community Gains Credibility

Drug prevention advocates who opposed cannabis legalisation based on public health concerns now find their positions strengthened by market evidence. The cannabis industry downturn provides tangible proof that marijuana normalisation creates societal costs without delivering promised benefits.

Community-based prevention programmes can point to the industry’s financial failures as evidence that cannabis legalisation was driven more by corporate profit motives than genuine social reform. This market collapse strengthens arguments for evidence-based drug policy focused on prevention rather than commercialisation.

Lessons for Future Policy Debates

The cannabis market collapse offers crucial insights for future substance policy debates. Prevention advocates can demonstrate how industry promises about responsible regulation and economic benefits proved fundamentally false when subjected to market reality.

The spectacular failure of cannabis commercialisation validates prevention-focused approaches that prioritise community health over corporate profits. Policymakers considering other substance liberalisation policies should examine how cannabis industry promises failed to materialise.

Strengthening Prevention Messaging

The cannabis industry downturn provides prevention organisations with powerful evidence about the dangers of drug normalisation. The sector’s collapse demonstrates that substance commercialisation creates market dynamics incompatible with public health priorities.

Prevention educators can use the cannabis market collapse to illustrate how corporate interests in substance markets inevitably conflict with community wellbeing. The industry’s financial failures prove that sustainable drug commerce requires exploitation of vulnerable populations.

The spectacular cannabis market collapse serves as a vindication of prevention advocates’ longstanding warnings about marijuana commercialisation. As the industry’s promises crumble alongside its valuations, the wisdom of prevention-focused drug policy becomes increasingly apparent. (Source: Reuters)

Details

Published: 10 September 2025

Hits: 381

Australia's medicines regulator has not investigated the safety of most medicinal cannabis products despite receiving hundreds of "adverse event" reports ranging from coughing to psychosis in the past three years.

The ABC can reveal there were 615 reports made to the Therapeutic Goods Administration (TGA) involving unregistered medicinal cannabis products between July 1, 2022 and June 1, 2025.

A TGA spokesperson said it had the power to investigate unapproved cannabis medications when "safety signals" — red flags for possible safety concerns —were identified.

"To date, no such signals for specific unapproved medicinal cannabis products have been identified and no investigations have occurred," the spokesperson said.

There are more than 1,000 different medicinal cannabis products currently available in Australia.

Apart from two products — which are listed on the Australian Register of Therapeutic Goods — the TGA has not approved or assessed any for quality, safety or efficacy.

While health professionals are required to report adverse events for unregistered products, the TGA generally keeps these reports on an internal database used for "general safety monitoring".

The TGA said when clinicians prescribed an unapproved medicine, they assumed responsibility for the "efficacy and safety of that good".

Psychiatrists say companies prioritising profit over safety

Chair of the Queensland branch of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) Brett Emmerson believed the 615 adverse events reported between July 2022 and June 2023 were the tip of the iceberg.

Last year, Professor Emmerson told the ABC his colleagues had seen a significant increase in people hospitalised with psychosis after being prescribed medicinal cannabis.

"The industry continues to market medicinal cannabis for a wide variety of conditions for which there is no evidence that it works," he said.

"They market it because people take it and that's their business.

"The medicinal cannabis companies are just like the tobacco companies — they want people to use their product, that's how they make their money and their profit."

Professor Emmerson is calling for greater regulatory oversight of medicinal cannabis.

He said companies should be required to prove specific products were safe and effective treatment for conditions before the medication could be prescribed.

"This is not a drug that can be just regarded as a natural product," he said.

"It's a drug of dependence with serious side effects and it's having a tragic impact on a large number of people in this country."

(For complete story ABC News 10th September 2025^thABC News 10th September 2025)

Details

Published: 10 September 2025

Hits: 449

Groundbreaking research from the Sorbonne has uncovered disturbing evidence linking youth marijuana suicide rates to regular cannabis consumption amongst teenagers. Furthermore, the study reveals that adolescent cannabis suicidal behaviours increase dramatically with marijuana use, even after accounting for existing mental health conditions.

Shocking Statistics Emerge: The French researchers discovered that young people who use marijuana face 46% higher odds of experiencing suicidal thoughts. Moreover, the cannabis-suicide connection becomes even more alarming when examining suicide attempts, with users showing 85% higher odds compared to non-users.

Significantly, the research methodology controlled for pre-existing depression, demonstrating that cannabis independently damages adolescent mental health. Consequently, these findings add to mounting evidence that adolescent cannabis suicidal ideation stems directly from marijuana consumption rather than underlying psychological conditions.

Prevention Becomes Critical: The Sorbonne study reinforces concerns about prevention strategies for at-risk teenagers. Additionally, previous research has established connections between cannabis use and severe mental health disorders, including schizophrenia. Therefore, experts emphasise that early intervention programmes targeting teenage substance use could prove vital in reducing tragic outcomes.

These alarming statistics suggest that addressing adolescent cannabis suicidal behaviours requires immediate action from parents, educators, and policymakers. Indeed, when youth marijuana suicide risks reach such concerning levels, prevention becomes a matter of life and death for vulnerable young people across communities nationwide. (Source: WRD News)

Details

Published: 10 September 2025

Hits: 493

Growing evidence suggests that cannabis immunotherapy risks may significantly compromise cancer treatment outcomes, according to a comprehensive new review by Australian medical cannabis advocate Dr Ben Jansen. Furthermore, his research poses a critical question that could reshape patient care protocols: “Are cannabinoids with cancer immunotherapy contributing to early death?”

Subsequently, Dr Jansen’s newly published study examines three key clinical trials that reveal troubling patterns in treatment effectiveness. Meanwhile, the findings challenge the widespread assumption that medical cannabis provides only benefits for cancer patients.

Personal Tragedy Drives Scientific Investigation

However, Dr Jansen’s investigation into medical marijuana treatment dangers stems from deeply personal circumstances surrounding his mother’s death from dementia. Moreover, he explained to Newsweek that discovering medicinal cannabis might have offered her relief motivated his advocacy work in the field.

“Over time, we’ve come to recognise the immunomodulatory properties of cannabinoids, which raised caution in my mind about their interaction with immune-based treatments,” Dr Jansen stated. Consequently, his concerns intensified when both the public and clinicians appeared unaware of potential cannabis immunotherapy risks.

Additionally, the issue “crystallised” during a public lecture when a patient questioned why her immunotherapy wasn’t working, only to reveal she had been taking high doses of medicinal cannabis.

Alarming Treatment Response Rates

Nevertheless, the first study Dr Jansen analysed compared patients receiving nivolumab immunotherapy alone with those combining the treatment with cannabis. In particular, the research examined 89 patients on nivolumab alone versus 51 patients using both treatments for advanced cancers including lung cancer, renal cell carcinoma, and melanoma.

The results revealed stark differences in treatment effectiveness, with cannabis users showing significantly lower response rates (15.9% versus 37.5%). Thus, patients using cannabis were approximately three times more likely to experience poor responses to immunotherapy, highlighting serious medical marijuana treatment dangers.

Importantly, whilst cannabis use didn’t significantly impact overall survival rates, the reduced treatment efficacy raises substantial concerns about therapeutic outcomes.

Shortened Survival Times Documented

Similarly, the second study examined 34 patients prescribed both immunotherapy and cannabis compared with 68 patients receiving cancer treatment alone. Furthermore, the findings revealed that tumours progressed much faster in cannabis users, typically within three-and-a-half months compared to over a year for patients on immunotherapy alone.

Moreover, the median overall survival time for cannabis users was dramatically shorter at 6.4 months compared to 28.5 months for non-users. Therefore, these statistics underscore the potential severity of cannabis immunotherapy risks for patient outcomes.

Comprehensive Analysis Confirms Concerns

Meanwhile, the third study investigated 105 patients with solid organ tumours receiving immune checkpoint inhibitors, with cannabis use primarily through prescribed dronabinol. Additionally, this research confirmed previous findings about medical marijuana treatment dangers.

Cannabis use was associated with significantly worse outcomes across multiple measures: shorter median overall survival (6.7 versus 17.3 months), reduced progression-free survival (4.8 versus 9.7 months), and markedly lower disease control rates (10.7% versus 37.7%).

Notably, these negative outcomes were most evident in white patients, suggesting potential ethnic variations in cannabinoid metabolism or immune response.

Complex Therapeutic Interactions

However, Dr Jansen acknowledges the inherent complexity of cannabis as a therapeutic agent when considering cannabis immunotherapy risks. Indeed, previous research has demonstrated that cannabis can suppress immune system function through active compounds including CBD, THC, and other cannabinoids.

Conversely, laboratory and living organism studies have suggested that cannabinoids can kill cancer cells and prevent spreading. Therefore, this paradox creates significant challenges for healthcare providers weighing treatment options whilst considering medical marijuana treatment dangers.

Clinical Recommendations and Future Research

Consequently, Dr Jansen emphasises the critical importance of informed patient consent regarding potential interactions. In addition, he advocates for more thorough research controlling variables such as cancer type, cannabis dosage, socio-economic status, and lifestyle factors.

When asked whether he would prescribe medical cannabis during immunotherapy, Dr Jansen responded definitively: “Absolutely” not, citing current evidence suggesting possible negative interactions.

Finally, until large, well-controlled trials provide clarity about cannabis immunotherapy risks, medical practitioners must carefully balance symptom management benefits against potential treatment compromise, ensuring patient safety remains the primary consideration.

Source: Newsweek